Tango Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Tango Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2020 to 2023.
  • Tango Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$29.6M, a 27.1% decline year-over-year.
  • Tango Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$132M, a 16.2% decline year-over-year.
  • Tango Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$114M, a 2.79% decline from 2022.
  • Tango Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$111M, a 90.9% decline from 2021.
  • Tango Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$58.2M, a 11.5% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$114M -$3.1M -2.79% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-18
2022 -$111M -$52.9M -90.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-18
2021 -$58.2M -$5.99M -11.5% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-27
2020 -$52.2M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.